【佳学基因检测】表皮生长因子受体突变状态对 IB-IIIA 期原发性肺腺癌无反复生存的预后因素

深圳品牌基因检测费用香港

根据基因检测结果分析中的基因解码方法发现《BMC Cancer》在. 2022 Sep 9;22(1):966.发表了一篇题目为《表皮生长因子受体突变状态对 IB-IIIA 期原发性肺腺癌无反复生存的预后因素》dota2吧雷电竞 dota2吧雷电竞 治疗基因检测临床研究文章。该研究由Tetsuya Isaka, Hiroyuki Ito, Tomoyuki Yokose, Haruhiro Saito, Hiroyuki Adachi, Kotaro Murakami, Jun Miura, Noritake Kikunishi, Yasushi Rino 等完成。促进了dota2吧雷电竞 的正确治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤靶向药物及正确治疗临床研究内容关键词：

辅助化疗, EGFR突变,病理阶段,原发性肺腺癌,无反复生存

肿瘤靶向治疗基因检测临床应用结果

背景：具有表皮生长因子受体 (EGFR) 突变 (Mt) 的病理分期 IB-IIIA 肺腺癌即使在有效切除后也具有高反复率。然而，关于 Mt 反复的危险因素的报道很少。本研究旨在分析伴有和不伴有 EGFR 突变的病理分期 IB-IIIA 原发性肺腺癌患者的无反复生存期 (无反复生存期) 相关的临床病理因素。方法：接受 Mt 治好性手术的患者 (n = 208)包括 2010 年 1 月至 2020 年 12 月期间携带 EGFR 外显子 21 L858R 点突变或 EGFR 外显子 19 缺失突变和 EGFR 突变野生型肺腺癌（Wt，n = 358）。接受辅助EGFR-酪氨酸激酶抑制剂的患者被排除在外。使用多变量 Cox 回归分析分析 无反复生存期 的预后因素。结果：Mt 组和 Wt 组的 5 年 无反复生存期 率分别为 43.5% 和 52.3% (p = 0.907)。 Mt 组 无反复生存期 的预后因素包括吸烟史（风险比 [HR]，1.49；p = 0.049）、血管侵犯（HR，1.84；p = 0.023）和淋巴结转移（HR，1.96；p = 0.005） ）。然而，辅助化疗不是预后因素（HR，1.02；p = 0.906）。相比之下，正电子发射断层扫描 (PET) 贼大标准化摄取值 (SUV) ≥ 6.0 (HR, 1.53; p = 0.042), 淋巴管浸润 (HR, 1.54; p = 0.036), 淋巴结转移 (HR, 1.79; p = 0.002）和辅助化疗（HR，0.60；p = 0.008）是 Wt 组 无反复生存期 的预后因素。结论： IB-IIIA 期原发性肺腺癌 无反复生存期 的预后因素因表皮生长因子受体突变状态而异。辅助化疗对 无反复生存期 的影响也因 EGFR 突变状态而异。 EGFR突变；病理阶段；原发性肺腺癌；无反复生存。

肿瘤发生与反复转移国际数据库描述：

Background: Pathological stage IB-IIIA lung adenocarcinoma with an epidermal growth factor receptor (EGFR) mutation (Mt) has a high recurrence rate even after complete resection. However, there have been few reports on the risk factors for Mt recurrence. This study aimed to analyze the clinicopathological factors related to the relapse-free survival (RFS) of patients with pathological stage IB-IIIA primary lung adenocarcinoma with and without an EGFR mutation.Methods: Patients who underwent curative surgery for Mt (n = 208) harboring the EGFR exon 21 L858R point mutation or EGFR exon 19 deletion mutation and EGFR mutation wild-type lung adenocarcinoma (Wt, n = 358) between January 2010 and December 2020 were included. Patients who received adjuvant EGFR-tyrosine kinase inhibitors were excluded. The prognostic factors for RFS were analyzed using a multivariable Cox regression analysis.Results: The 5-year RFS rates in the Mt and Wt groups were 43.5 and 52.3%, respectively (p = 0.907). Prognostic factors for RFS in the Mt group included smoking history (hazard ratio [HR], 1.49; p = 0.049), blood vessel invasion (HR, 1.84; p = 0.023), and lymph node metastasis (HR, 1.96; p = 0.005). However, adjuvant chemotherapy was not a prognostic factor (HR, 1.02; p = 0.906). In contrast, positron emission tomography (PET) max standardized uptake value (SUV) ≥ 6.0 (HR, 1.53; p = 0.042), lymphatic vessel invasion (HR, 1.54; p = 0.036), lymph node metastasis (HR, 1.79; p = 0.002), and adjuvant chemotherapy (HR, 0.60; p = 0.008) were prognostic factors for RFS in the Wt group.Conclusions: Prognostic factors for RFS in stage IB-IIIA primary lung adenocarcinoma differ by epidermal growth factor receptor mutation status. The impact of adjuvant chemotherapy on RFS also differed by EGFR mutation status.Keywords: Adjuvant chemotherapy; EGFR mutation; Pathological stage; Primary lung adenocarcinoma; Relapse-free survival.